gdc

Lymphoma

Drugs for Lymphoma
Lymphoma
Find financial assistance programs available for lymphoma drugs.
Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
FDA Approvals, News & UpdatesLymphoma
In September 2021, the FDA approved Brukinsa oral capsules for adults with relapsed or refractory marginal-zone lymphoma. And in August, the FDA approved Brukinsa for adults with Waldenström’s macroglobulinemia, a rare, slow-growing type of non-Hodgkin lymphoma.
FDA Approved Rylaze as Part of a Treatment Regimen for Young Patients with Leukemia or Lymphoma
FDA Approvals, News & UpdatesLeukemiaLymphoma
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection.
Zynlonta First FDA-Approved CD19-Targeted Therapy for Large B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
In April 2021, the FDA approved Zynlonta (loncastuximab tesirine), the first CD19-directed antibody–drug conjugate, for the treatment of patients with relapsed or refractory large B-cell lymphoma.
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
FDA Approvals, News & UpdatesLymphomaFollicular Lymphoma
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.
Page 1 of 7
Results 1 - 10 of 62

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests